Business Wire

Celltrion Healthcare: UK Lags behind Most of Europe in Access to Biologics for Patients with Rheumatoid Arthritis

Del

Celltrion Healthcare calls for the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA) and to put plans in place to increase patient access to biological treatment.

According to recent findings published in the Annals of the Rheumatic Diseases, disease activity and the use of biological disease-modifying anti-rheumatic drugs among patients with RA vary from country to country, due to different contributing factors, such as per capita GDP, drug affordability and reimbursement policies.1

There are set thresholds in disease activity before biologics can be used in RA patients, but these thresholds vary across Europe. The percentage of patients who are treated with an anti-TNF-α (an effective class of treatment that reduces inflammation and pain) is 24% or higher in countries such as Italy and France, however, in the UK this drops to just 15%. This is because in the UK a patient must have a higher DAS-28 (a measure of how severe the disease is) threshold of 5.1 compared to only 3.2 in other European countries. 2,3,4 Despite the National Institute for Health and Care Excellence (NICE) widely acknowledging that appropriate biological treatments are clinically effective for all subgroups of RA patients, access to these therapies remains restricted in UK on grounds of cost-effectiveness.5

Speaking at the Health and Care Innovation Expo 2018 taking place on 5 and 6 September, Dr. Ben Parker, Consultant Rheumatologist, Manchester University Hospitals, NHS Foundation Trust says, “A UK patient’s burden of disease must be much more severe before they qualify for biologic therapy, compared to a French patient. As a treating physician, I strongly believe that this inequality needs to be addressed so that our patients can realize the same benefits of early treatment as their European neighbors.”

The National Rheumatoid Arthritis Society (NRAS) and British Society for Rheumatology (BSR) concur that in the UK “eligibility criteria (DAS-28 of more than 5.1) are set too high.” and state, within their “Biologics…The Story So Far” publication, that “The BSR and others, including NRAS, will continue to make the case to NICE for reducing the required DAS-28 score from 5.1”.6

According to NHS’s recent savings data, NHS England saved £324m in the last financial year by switching from using 10 higher priced medicines to better value biosimilars and generic medicines which are considered to be equally effective and safe alternatives. Switching patients to biosimilars of these biologics led to significant cost savings: infliximab biosimilars delivered £99.4 million in savings, etanercept biosimilars delivered £60.3 million, and rituximab biosimilars delivered £50.4 million, for a cumulative savings of over £220 million in cancer and autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases.7

Mr. HoUng Kim, Head of Strategy and Operations at Celltrion Healthcare said, “We have identified clear disparities in access to biologics across Europe. Patients diagnosed with less than severe disease activity should be able to get just as good and cost-effective benefit from biologics as patients with severely active disease, as this will help them achieve a better quality of life. With the proven savings, gained through the use of biosimilars, this could be a real opportunity for the NHS to address these concerning inequalities.”

--- Ends---

Notes to editors:

About rheumatoid arthritis

In Europe, more than 2.9 million people have rheumatoid arthritis (RA), many of whom are of working age. On average, every third person with RA becomes work disabled and up to 40 per cent leave work completely within 5 years of diagnosis.8 Although there is no cure for RA, there are many treatments that can reduce inflammation and ease pain. As with all rheumatic diseases early diagnosis and intervention is key.

About CT-P13 (biosimilar infliximab)

CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 88 countries (as of August 2018) including the US, Canada, Japan and throughout Europe.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/

_____________________________
1 Bergstra S, Branco J, Vega-Morales D et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. ARD 6 July 2018. Available at https://ard.bmj.com/content/early/2018/07/06/annrheumdis-2018-213289 [Last accessed August 2018].
2 Deighton C, Hyrich K, Ding T et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 2010; 49 (6): 1197–1199.
3 Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008; 8 (2): 61–86.
4 Global Data Forecast and Market Analysis – Rheumatoid Arthritis. Published January 2017 [Last accessed August 2018]
5 NICE Technology appraisal guidance [TA375]. Published: 26 January 2016. Available at https://www.nice.org.uk/guidance/ta375 [Last accessed August 2018].
6 National Rheumatoid Arthritis Society. Biologics... The Story So Far. September 2013. Pg 29. Available at https://www.nras.org.uk/data/files/Publications/Biologics-.pdf [Last accessed August 2018].
7 NHS Improvement UK. The NHS saves £324 million in a year by switching to better value medicines. Published 31 July 2018. Available at https://improvement.nhs.uk/news-alerts/nhs-saves-324-million-year-switching-better-value-medicines/ [Last accessed August 2018].
8 NRAS, European Fit for Work Report. Available at www.nras.org.uk/european-fit-for-work-report. [Last accessed August 2018].

Contact information

Hanover Communications
Suru Douglas
sdouglas@hanovercomms.com
+44 203 817 6586
or
Georgia Featherston
gfeatherston@hanovercomms.com
+44 203 817 6718

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

SimScale Releases Major User Interface Update for a Better Simulation Experience in the Cloud26.9.2018 12:34Pressemelding

SimScale, the provider of the world’s first production-ready SaaS application for engineering simulation, announced today the release of their new workbench. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005496/en/ Conjugate heat transfer simulation of an electronics enclosure with SimScale (Graphic: Business Wire) SimScale Workbench 2.0 was built entirely from scratch on the latest, state-of-the-art technology stack, with the goal of drastically improving user productivity by decreasing loading time and increasing interaction speed. The SimScale web-based CAE platform is now as fast and interactive as a desktop application while taking advantage of the unlimited computing power of the cloud. Furthermore, the new solution stack sets the stage for major new features that are already in development and will be released soon. “Right from the start I love it! Well done. This is a really nice improvement,” said Ben Lewis,

MyHeritage er oppnevnt som hovedsponsor for the Eurovision Song Contest 201926.9.2018 12:09Pressemelding

MyHeritage, det ledende, globale slektshistorie og DNA-selskapet, er i dag blitt oppnevnt som hovedsponsor for Melodi Grand Prix 2019 av den Europeiske Kringkastingsunionen (EBU). MyHeritage har, som arrangementets hovedsponsor, fått omfattende global assosiasjon og arrangement, media og digitale rettigheter i forbindelse med den kommende sangkonkurransen som vil finne sted i Tel Aviv. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20180926005471/no/ MyHeritages tjenester gjør det lett for hvem som helst, hvor som helst, å begi seg ut på en fascinerende oppdagelsesferd for å finne sine røtter. Ved hjelp av MyHeritage DNA-testen, MyHeritages integrerte slektstre-bygging-platform (Family Tree Builder) og samlinger bestående av ni milliarder historiske dokumenter, hjelper MyHeritage millioner av mennesker til å oppdage sine familiers fortid, og til å forstå hvordan de selv passer inn i den globale menneskelige mosaikken. De

Calldorado Selected as a Finalist of the 2018 Engage Awards26.9.2018 12:02Pressemelding

Calldorado ApS are proud to announce their selection as a finalist in the Best Employee Centric Strategy category of the Engage Awards 2018 – the only customer and employee engagement industry awards in the UK. Calldorado, a completely self-funded company, has grown exponentially in an incredibly short period of time, and this is reflected in the finalist list where it is shortlisted alongside giant brands such as Virgin Media and Bacardi. “We are delighted to be a finalist in the Best Employee Centric Strategy category of these prestigious awards. Our ethos from the very beginning has been to mix experienced expertise with young talent fresh from education. To nurture and develop the movers and shakers of tomorrow, whose careers will grow alongside the company. We operate on values of mutual trust and transparent sharing and listening. Everyone’s opinion has equal value, which inspires collaboration, and encourages thinking that leads to changes and product innovations which drive our

Slice Labs Raises $20M in Extended Series A to Globalize its On-Demand Insurance Cloud Platform26.9.2018 11:00Pressemelding

Slice Labs, a leading on-demand insurance cloud platform provider, today announced it has raised an additional $20 million in Series A funding, led by The Co-operators with participation from XL Innovate, Horizons, Munich Re/HSB Ventures, SOMPO, Veronorte, the investment arm of Grupo Sura, and JetBlue Technology Ventures. This sizable, extended round will be used to execute on the higher than planned global demand for Slice Insurance Cloud Services (ICS). Slice launched in 2016 with a mission to change, improve and redesign insurance. The company’s Insurance Cloud Services (ICS) is transforming traditional insurers into digitally-driven carriers by providing them with a platform that enables them to quickly ideate, experiment, test and deploy new, on-demand insurance products. Top global insurers have launched on-demand insurance products using ICS, and Slice will use this new financing to continue expanding its offering on a global scale. “The ICS platform is rapidly growing as insure

ZephyrTel Welcomes Vasona to Its Portfolio of Software Solutions Serving the Global Telecommunications Sector26.9.2018 10:01Pressemelding

ZephyrTel, an ESW Capital software company dedicated to serving the global telecommunications industry, is pleased to announce it has acquired Vasona Networks, a leader in network performance and edge computing software for mobile operators, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005376/en/ Mike Shinya, CEO of ZephyrTel (Photo: Business Wire) ZephyrTel is building a world-class telco practice, to provide a multi-solution and services proposition to the global telco industry and leading enterprises. The company’s primary objective is to offer software and SaaS solutions across telco companies IT estates; from infrastructure right through to customer experience. This, coupled with high levels of industry domain expertise, will enable it to offer consultancy on both business strategy and technology execution. Having already acquired several telecom software companies, ZephyrTel is currently

Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services26.9.2018 10:00Pressemelding

Scott J. Hinkle has joined Hallstar, the global specialty chemistry company, as Chief Financial Officer. He will be based in Hallstar’s corporate headquarters in Chicago, Illinois, reporting directly to Chairman and CEO, John J. Paro. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005216/en/ Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services (Photo: Business Wire) Founded in 1986, Hallstar has become widely recognized for its innovative expertise in the areas of photostability science, renewable plasticizers, eco-based actives, phthalate replacements, natural olive chemistry and polymer modification. The company boasts research and development, manufacturing, and sales operations in China, Italy, France, and Brazil, in addition to the United States. Hallstar recently announced a structural split into Hallstar Beauty and Hallstar Industrial, effective October 1, 2018. These two